FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884099841> ?p ?o ?g. }

• W2884099841 endingPage "S201" @default.
• W2884099841 startingPage "S201" @default.
• W2884099841 abstract "Introduction Post-transplant lymphoproliferative disorders (PTLD) represent a severe complication in transplant patients. Epstein-Barr Virus (EBV) is the main driver of PTLD, particularly of those occurring early after transplantation. Immune activation/inflammation, immune senescence, reactivation of EBV and expansion of EBV-positive B cells, which play a pivotal role in the onset of PTLD, may be modulated by immunosuppressive strategies. The aim of this study was to assess the impact of mTOR inhibitor (mTORi) on viral and host cofactors involved in the PTLD’s pathogenesis. Materials and Methods Sixty-two kidney transplant patients were enrolled in the study: 33 were treated with mycophenolic acid (MPA) and 29 with mTORi, both in combination with tacrolimus and steroids. Thymoglobulin was the induction in all cases. All patients were assessed at the time of transplant and after 1 year of follow-up. Markers of T-cell activation(CD3+CD8+CD38+), exhaustion(CD3+CD8+PD-1+), senescence (CD3+CD8+CD28-CD57+), and B-cell activation (CD19+CD10-CD21lowCD27+) were evaluated by flow cytometry. Plasma levels of PAMPs(microbial translocation marker 16s ribosomal(r)DNA) and DAMPs(mitochondrial(mt)DNA) were quantified by real-time PCR. Inflammatory cytokines (IL-6 and TNF-alpha) were quantified by Luminex platform. EBV was typed and quantified by multiplex real-time PCR, and telomere lengths in peripheral blood cells (PBMC) were estimated by telomere/single copy gene ratio (T/S), using multiplex real-time PCR. Results After 1 year of follow-up, plasma levels of 16s rDNA increased in MPA-treated patients (p=0.029), while remained stable in the mTORi group. Levels of mtDNA and pro- inflammatory cytokines tended to decrease in mTORi-treated patients (mtDNA, p=0.034; IL-6, p=0.08; TNF-alpha, p<0.001), while no significant changes were observed in the MPA group. Percentages of activated, exhausted and senescent T cells significantly increased in the MPA-treated patients (4.6[2.2-9.1] vs 17.8[12.1-23.3],p<0.001; 4.8[3.0-6.9] vs 11.6[8.7-16.8],p<0.001; and 7.9[4.4-14.5] vs 14.5[8.5-27.7],p=0.005), but remained stable in the mTORi group (2.4[1.8-6.1] vs 4.1[2.4-6.3], p=0.161; 6.4[4.9-12.1] vs 7.1[4.3-12.7],p=0.888; and 9.7[5.2-13.8]vs 10.8[5.6-16.2],p=0.460). The increase in immunosenescent cells in the MPA group was supported by telomere shortening, higher in MPA than in mTORi-treated patients (ΔT/S=-0.449 vs ΔT/S=-0.219). Percentages of activated B cells and levels of EBV-DNA significantly increased in the MPA group (10.3[6.4-16.9] vs 18.3[11.6-28.4],p=0.002, and 1[1-17] vs 27[1-118] EBV-DNA copies/105 PBMC, p=0.004), while remained stable in the mTORi group (12.8[6.8-18.8]vs 13.0[9.2-18.0], p=0.836, and 1[1-7]vs 6[1-26] EBV-DNA copies/105 PBMC, p=0.128). Conclusions mTORi maintained low levels of pro-inflammatory cytokines, immune activation and senescence, thus constraining EBV reactivation and expansion of EBV-positive B cells. Overall, these findings suggest that mTORi may reduce the risk of EBV-related malignancies in kidney transplant patients. AIRC grant IG2016 Id 19112." @default.
• W2884099841 created "2018-08-03" @default.
• W2884099841 creator A5006753881 @default.
• W2884099841 creator A5006926500 @default.
• W2884099841 creator A5017943795 @default.
• W2884099841 creator A5017987660 @default.
• W2884099841 creator A5018219750 @default.
• W2884099841 creator A5019182161 @default.
• W2884099841 creator A5039363989 @default.
• W2884099841 creator A5045869959 @default.
• W2884099841 creator A5050464219 @default.
• W2884099841 creator A5055765319 @default.
• W2884099841 creator A5090974373 @default.
• W2884099841 date "2018-07-01" @default.
• W2884099841 modified "2023-10-14" @default.
• W2884099841 title "mTOR Inhibitors Maintain Low Levels of Immune Activation, Immune Senescence and EBV Load in Kidney Transplant Patients" @default.
• W2884099841 doi "https://doi.org/10.1097/01.tp.0000542853.14246.b2" @default.
• W2884099841 hasPublicationYear "2018" @default.
• W2884099841 type Work @default.
• W2884099841 sameAs 2884099841 @default.
• W2884099841 citedByCount "0" @default.
• W2884099841 crossrefType "journal-article" @default.
• W2884099841 hasAuthorship W2884099841A5006753881 @default.
• W2884099841 hasAuthorship W2884099841A5006926500 @default.
• W2884099841 hasAuthorship W2884099841A5017943795 @default.
• W2884099841 hasAuthorship W2884099841A5017987660 @default.
• W2884099841 hasAuthorship W2884099841A5018219750 @default.
• W2884099841 hasAuthorship W2884099841A5019182161 @default.
• W2884099841 hasAuthorship W2884099841A5039363989 @default.
• W2884099841 hasAuthorship W2884099841A5045869959 @default.
• W2884099841 hasAuthorship W2884099841A5050464219 @default.
• W2884099841 hasAuthorship W2884099841A5055765319 @default.
• W2884099841 hasAuthorship W2884099841A5090974373 @default.
• W2884099841 hasConcept C10205521 @default.
• W2884099841 hasConcept C126322002 @default.
• W2884099841 hasConcept C142462285 @default.
• W2884099841 hasConcept C159912055 @default.
• W2884099841 hasConcept C167672396 @default.
• W2884099841 hasConcept C203014093 @default.
• W2884099841 hasConcept C2522874641 @default.
• W2884099841 hasConcept C2780303639 @default.
• W2884099841 hasConcept C28328180 @default.
• W2884099841 hasConcept C2909675724 @default.
• W2884099841 hasConcept C2911091166 @default.
• W2884099841 hasConcept C54355233 @default.
• W2884099841 hasConcept C71924100 @default.
• W2884099841 hasConcept C86803240 @default.
• W2884099841 hasConcept C8891405 @default.
• W2884099841 hasConceptScore W2884099841C10205521 @default.
• W2884099841 hasConceptScore W2884099841C126322002 @default.
• W2884099841 hasConceptScore W2884099841C142462285 @default.
• W2884099841 hasConceptScore W2884099841C159912055 @default.
• W2884099841 hasConceptScore W2884099841C167672396 @default.
• W2884099841 hasConceptScore W2884099841C203014093 @default.
• W2884099841 hasConceptScore W2884099841C2522874641 @default.
• W2884099841 hasConceptScore W2884099841C2780303639 @default.
• W2884099841 hasConceptScore W2884099841C28328180 @default.
• W2884099841 hasConceptScore W2884099841C2909675724 @default.
• W2884099841 hasConceptScore W2884099841C2911091166 @default.
• W2884099841 hasConceptScore W2884099841C54355233 @default.
• W2884099841 hasConceptScore W2884099841C71924100 @default.
• W2884099841 hasConceptScore W2884099841C86803240 @default.
• W2884099841 hasConceptScore W2884099841C8891405 @default.
• W2884099841 hasIssue "Supplement 7" @default.
• W2884099841 hasLocation W28840998411 @default.
• W2884099841 hasOpenAccess W2884099841 @default.
• W2884099841 hasPrimaryLocation W28840998411 @default.
• W2884099841 hasRelatedWork W1839244838 @default.
• W2884099841 hasRelatedWork W2020054062 @default.
• W2884099841 hasRelatedWork W2027970569 @default.
• W2884099841 hasRelatedWork W2132735695 @default.
• W2884099841 hasRelatedWork W2370117545 @default.
• W2884099841 hasRelatedWork W2389946526 @default.
• W2884099841 hasRelatedWork W27843084 @default.
• W2884099841 hasRelatedWork W3029630957 @default.
• W2884099841 hasRelatedWork W3083533106 @default.
• W2884099841 hasRelatedWork W4200293125 @default.
• W2884099841 hasVolume "102" @default.
• W2884099841 isParatext "false" @default.
• W2884099841 isRetracted "false" @default.
• W2884099841 magId "2884099841" @default.
• W2884099841 workType "article" @default.